newsfilter
← Latest News
Business Wire·

NIH/NIAID Locks ACTIV-5/BET-B Database

Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, confirms that notice was receive